Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Respiratory Microbiota | Review

The potential impact of a probiotic: Akkermansia muciniphila in the regulation of blood pressure—the current facts and evidence

Authors: Arun Prasath Lakshmanan, Selvasankar Murugesan, Souhaila Al Khodor, Annalisa Terranegra

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Akkermansia muciniphila (A. muciniphila) is present in the human gut microbiota from infancy and gradually increases in adulthood. The potential impact of the abundance of A. muciniphila has been studied in major cardiovascular diseases including elevated blood pressure or hypertension (HTN). HTN is a major factor in premature death worldwide, and approximately 1.28 billion adults aged 30–79 years have hypertension. A. muciniphila is being considered a next-generation probiotic and though numerous studies had highlighted the positive role of A. muciniphila in lowering/controlling the HTN, however, few studies had highlighted the negative impact of increased abundance of A. muciniphila in the management of HTN. Thus, in the review, we aimed to discuss the current facts, evidence, and controversy about the role of A. muciniphila in the pathophysiology of HTN and its potential effect on HTN management/regulation, which could be beneficial in identifying the drug target for the management of HTN.
Literature
1.
Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54:1469–76.PubMedCrossRef
2.
Ouwerkerk JP, Aalvink S, Belzer C, de Vos WM. Akkermansia glycaniphila sp. nov., an anaerobic mucin-degrading bacterium isolated from reticulated python faeces. Int J Syst Evol Microbiol. 2016;66:4614–20.PubMedCrossRef
3.
Karcher N, Nigro E, Puncochar M, Blanco-Miguez A, Ciciani M, Manghi P, Zolfo M, Cumbo F, Manara S, Golzato D, et al. Genomic diversity and ecology of human-associated Akkermansia species in the gut microbiome revealed by extensive metagenomic assembly. Genome Biol. 2021;22:209.PubMedPubMedCentralCrossRef
4.
Caputo A, Dubourg G, Croce O, Gupta S, Robert C, Papazian L, Rolain JM, Raoult D. Whole-genome assembly of Akkermansia muciniphila sequenced directly from human stool. Biol Direct. 2015;10:5.PubMedPubMedCentralCrossRef
5.
Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl Environ Microbiol. 2008;74:1646–8.PubMedCrossRef
6.
7.
Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog. 2017;106:171–81.PubMedCrossRef
8.
Liu X, Zhao F, Liu H, Xie Y, Zhao D, Li C. Transcriptomics and metabolomics reveal the adaption of Akkermansia muciniphila to high mucin by regulating energy homeostasis. Sci Rep. 2021;11:9073.PubMedPubMedCentralCrossRef
9.
Hanninen A, Toivonen R, Poysti S, Belzer C, Plovier H, Ouwerkerk JP, Emani R, Cani PD, De Vos WM. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut. 2018;67:1445–53.PubMedCrossRef
10.
Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia Muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe−/− Mice. Circulation. 2016;133:2434–46.PubMedCrossRef
11.
Kim S, Lee Y, Kim Y, Seo Y, Lee H, Ha J, Lee J, Choi Y, Oh H, Yoon Y. Akkermansia muciniphila prevents fatty liver disease, decreases serum triglycerides, and maintains gut homeostasis. Appl Environ Microbiol. 2020;86:e03004-19PubMedPubMedCentralCrossRef
12.
Lau WL, Vaziri ND, Nunes ACF, Comeau AM, Langille MGI, England W, Khazaeli M, Suematsu Y, Phan J, Whiteson K. The phosphate binder ferric citrate alters the gut microbiome in rats with chronic kidney disease. J Pharmacol Exp Ther. 2018;367:452–60.PubMedCrossRef
13.
14.
de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velasquez-Mejia EP, Carmona JA, Abad JM, Escobar JS. Metformin Is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 2017;40:54–62.PubMedCrossRef
15.
Panebianco C, Adamberg K, Jaagura M, Copetti M, Fontana A, Adamberg S, Kolk K, Vilu R, Andriulli A, Pazienza V. Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice. Cancer Chemother Pharmacol. 2018;81:773–82.PubMedCrossRef
16.
Ramakrishna C, Corleto J, Ruegger PM, Logan GD, Peacock BB, Mendonca S, Yamaki S, Adamson T, Ermel R, McKemy D, et al. Dominant role of the gut microbiota in chemotherapy induced neuropathic pain. Sci Rep. 2019;9:20324.PubMedPubMedCentralCrossRef
17.
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7.PubMedCrossRef
18.
Su H, Mo J, Ni J, Ke H, Bao T, Xie J, Xu Y, Xie L, Chen W. Andrographolide exerts antihyperglycemic effect through strengthening intestinal barrier function and increasing microbial composition of Akkermansia muciniphila. Oxid Med Cell Longev. 2020;2020:6538930.PubMedPubMedCentralCrossRef
19.
Wang L, Wu Y, Zhuang L, Chen X, Min H, Song S, Liang Q, Li AD, Gao Q. Puerarin prevents high-fat diet-induced obesity by enriching Akkermansia muciniphila in the gut microbiota of mice. PLoS ONE. 2019;14:e0218490.PubMedPubMedCentralCrossRef
20.
Fujisaka S, Usui I, Nawaz A, Igarashi Y, Okabe K, Furusawa Y, Watanabe S, Yamamoto S, Sasahara M, Watanabe Y, et al. Bofutsushosan improves gut barrier function with a bloom of Akkermansia muciniphila and improves glucose metabolism in mice with diet-induced obesity. Sci Rep. 2020;10:5544.PubMedPubMedCentralCrossRef
21.
Chen M, Hou P, Zhou M, Ren Q, Wang X, Huang L, Hui S, Yi L, Mi M. Resveratrol attenuates high-fat diet-induced non-alcoholic steatohepatitis by maintaining gut barrier integrity and inhibiting gut inflammation through regulation of the endocannabinoid system. Clin Nutr. 2020;39:1264–75.PubMedCrossRef
22.
Wahlstrom A, Sayin SI, Marschall HU, Backhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24:41–50.PubMedCrossRef
23.
Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63:727–35.PubMedCrossRef
24.
Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA. 2013;110:9066–71.PubMedPubMedCentralCrossRef
25.
Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017;5:14.PubMedPubMedCentralCrossRef
26.
Canale MP, Noce A, Di Lauro M, Marrone G, Cantelmo M, Cardillo C, Federici M, Di Daniele N, Tesauro M. Gut dysbiosis and western diet in the pathogenesis of essential arterial hypertension: a narrative review. Nutrients. 2021;13:1162.PubMedPubMedCentralCrossRef
27.
Sun S, Lulla A, Sioda M, Winglee K, Wu MC, Jacobs DR Jr, Shikany JM, Lloyd-Jones DM, Launer LJ, Fodor AA, Meyer KA. Gut microbiota composition and blood pressure. Hypertension. 2019;73:998–1006.PubMedCrossRef
28.
Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65:1331–40.PubMedCrossRef
29.
Afsar B, Vaziri ND, Aslan G, Tarim K, Kanbay M. Gut hormones and gut microbiota: implications for kidney function and hypertension. J Am Soc Hypertens. 2016;10:954–61.PubMedCrossRef
30.
Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116:960–75.CrossRef
31.
Travers A, Farber HW, Sarnak MJ. Pulmonary hypertension in chronic kidney disease. Cardiol Clin. 2021;39:427–34.PubMedCrossRef
32.
Patel RS, Masi S, Taddei S. Understanding the role of genetics in hypertension. Eur Heart J. 2017;38:2309–12.PubMedCrossRef
33.
Habeeb E, Aldosari S, Saghir SA, Cheema M, Momenah T, Husain K, Omidi Y, Rizvi SAA, Akram M, Ansari RA. Role of environmental toxicants in the development of hypertensive and cardiovascular diseases. Toxicol Rep. 2022;9:521–33.PubMedPubMedCentralCrossRef
34.
Verma N, Rastogi S, Chia YC, Siddique S, Turana Y, Cheng HM, Sogunuru GP, Tay JC, Teo BW, Wang TD, et al. Non-pharmacological management of hypertension. J Clin Hypertens. 2021;23:1275–83.CrossRef
35.
Vallianou NG, Geladari E, Kounatidis D. Microbiome and hypertension: where are we now? J Cardiovasc Med. 2020;21:83–8.CrossRef
36.
37.
Ding RX, Goh WR, Wu RN, Yue XQ, Luo X, Khine WWT, Wu JR, Lee YK. Revisit gut microbiota and its impact on human health and disease. J Food Drug Anal. 2019;27:623–31.PubMedPubMedCentralCrossRef
38.
Belizario JE, Faintuch J. Microbiome and gut dysbiosis. Exp Suppl. 2018;109:459–76.PubMed
39.
40.
Chen X, Li HY, Hu XM, Zhang Y, Zhang SY. Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure. Chin Med J. 2019;132:1843–55.PubMedPubMedCentralCrossRef
41.
Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Author correction: probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16:642.PubMedCrossRef
42.
Cheng D, Xie MZ. A review of a potential and promising probiotic candidate—Akkermansia muciniphila. J Appl Microbiol. 2021;130:1813–22.PubMedCrossRef
43.
Ottman N, Geerlings SY, Aalvink S, de Vos WM, Belzer C. Action and function of Akkermansia muciniphila in microbiome ecology, health and disease. Best Pract Res Clin Gastroenterol. 2017;31:637–42.PubMedCrossRef
44.
Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol. 2020;11:25.CrossRef
45.
Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc. 2003;62:67–72.PubMedCrossRef
46.
Liu P, Wang Y, Yang G, Zhang Q, Meng L, Xin Y, Jiang X. The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. Pharmacol Res. 2021;165:105420.PubMedCrossRef
47.
Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus H, Haase S, Mahler A, Balogh A, Marko L, et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature. 2017;551:585–9.PubMedPubMedCentralCrossRef
48.
Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003;278:11312–9.PubMedCrossRef
49.
Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S, Dupriez V, Vassart G, Van Damme J, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003;278:25481–9.PubMedCrossRef
50.
51.
Chang AJ, Ortega FE, Riegler J, Madison DV, Krasnow MA. Oxygen regulation of breathing through an olfactory receptor activated by lactate. Nature. 2015;527:240–4.PubMedPubMedCentralCrossRef
52.
53.
Aisenberg WH, Huang J, Zhu W, Rajkumar P, Cruz R, Santhanam L, Natarajan N, Yong HM, De Santiago B, Oh JJ, et al. Defining an olfactory receptor function in airway smooth muscle cells. Sci Rep. 2016;6:38231.PubMedPubMedCentralCrossRef
54.
55.
Neuhaus EM, Zhang W, Gelis L, Deng Y, Noldus J, Hatt H. Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem. 2009;284:16218–25.PubMedPubMedCentralCrossRef
56.
Gelis L, Jovancevic N, Veitinger S, Mandal B, Arndt HD, Neuhaus EM, Hatt H. Functional characterization of the odorant receptor 51E2 in human melanocytes. J Biol Chem. 2016;291:17772–86.PubMedPubMedCentralCrossRef
57.
Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, Brunet I, Wan LX, Rey F, Wang T, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA. 2013;110:4410–5.PubMedPubMedCentralCrossRef
58.
Verhoog S, Taneri PE, Diaz ZMR, Marques-Vidal P, Troup JP, Bally L, Franco OH, Glisic M, Muka T. Dietary factors and modulation of bacteria strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: a systematic review. Nutrients. 2019;11:1565.PubMedCentralCrossRef
59.
Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65:426–36.PubMedCrossRef
60.
Remely M, Hippe B, Geretschlaeger I, Stegmayer S, Hoefinger I, Haslberger A. Increased gut microbiota diversity and abundance of Faecalibacterium prausnitzii and Akkermansia after fasting: a pilot study. Wien Klin Wochenschr. 2015;127:394–8.PubMedPubMedCentralCrossRef
61.
Lukovac S, Belzer C, Pellis L, Keijser BJ, de Vos WM, Montijn RC, Roeselers G. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids. mBio. 2014;5:e01438–14.PubMedPubMedCentralCrossRef
62.
Martins FL, Bailey MA, Girardi ACC. Endogenous activation of glucagon-like peptide-1 receptor contributes to blood pressure control: role of proximal tubule Na(+)/H(+) exchanger isoform 3, renal angiotensin II, and insulin sensitivity. Hypertension. 2020;76:839–48.PubMedCrossRef
63.
Pauza AG, Thakkar P, Tasic T, Felippe I, Bishop P, Greenwood MP, Rysevaite-Kyguoliene K, Ast J, Broichhagen J, Hodson DJ, et al. GLP1R attenuates sympathetic response to high glucose via carotid body inhibition. Circ Res. 2022;130:694–707.PubMedPubMedCentralCrossRef
64.
Zhao S, Liu W, Wang J, Shi J, Sun Y, Wang W, Ning G, Liu R, Hong J. Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice. J Mol Endocrinol. 2017;58:1–14.PubMedCrossRef
65.
Zaibi MS, Stocker CJ, O’Dowd J, Davies A, Bellahcene M, Cawthorne MA, Brown AJ, Smith DM, Arch JR. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett. 2010;584:2381–6.PubMedCrossRef
66.
Hong YH, Nishimura Y, Hishikawa D, Tsuzuki H, Miyahara H, Gotoh C, Choi KC, Feng DD, Chen C, Lee HG, et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology. 2005;146:5092–9.PubMedCrossRef
67.
Li C, Xiao P, Lin D, Zhong HJ, Zhang R, Zhao ZG, He XX. Risk factors for intestinal barrier impairment in patients with essential hypertension. Front Med. 2020;7:543698.CrossRef
68.
Sperandeo P, Martorana AM, Polissi A. Lipopolysaccharide biogenesis and transport at the outer membrane of Gram-negative bacteria. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862:1451–60.PubMedCrossRef
69.
70.
Carpenter TS, Parkin J, Khalid S. The free energy of small solute permeation through the escherichia coli outer membrane has a distinctly asymmetric profile. J Phys Chem Lett. 2016;7:3446–51.PubMedCrossRef
71.
Rosadini CV, Kagan JC. Early innate immune responses to bacterial LPS. Curr Opin Immunol. 2017;44:14–9.PubMedCrossRef
72.
Kim S, Goel R, Kumar A, Qi Y, Lobaton G, Hosaka K, Mohammed M, Handberg EM, Richards EM, Pepine CJ, Raizada MK. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci. 2018;132:701–18.CrossRef
73.
Anhe FF, Jensen BAH, Perazza LR, Tchernof A, Schertzer JD, Marette A. Bacterial postbiotics as promising tools to mitigate cardiometabolic diseases. J Lipid Atheroscler. 2021;10:123–9.PubMedPubMedCentralCrossRef
74.
Raftar SKA, Ashrafian F, Abdollahiyan S, Yadegar A, Moradi HR, Masoumi M, Vaziri F, Moshiri A, Siadat SD, Zali MR. The anti-inflammatory effects of Akkermansia muciniphila and its derivates in HFD/CCL4-induced murine model of liver injury. Sci Rep. 2022;12:2453.PubMedPubMedCentralCrossRef
75.
Chelakkot C, Choi Y, Kim DK, Park HT, Ghim J, Kwon Y, Jeon J, Kim MS, Jee YK, Gho YS, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med. 2018;50:e450.PubMedPubMedCentralCrossRef
76.
Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y. Function of Akkermansia muciniphila in obesity: interactions with lipid metabolism, immune response and gut systems. Front Microbiol. 2020;11:219.PubMedPubMedCentralCrossRef
77.
Ottman N, Reunanen J, Meijerink M, Pietila TE, Kainulainen V, Klievink J, Huuskonen L, Aalvink S, Skurnik M, Boeren S, et al. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS ONE. 2017;12:e0173004.PubMedPubMedCentralCrossRef
78.
Shin J, Noh JR, Chang DH, Kim YH, Kim MH, Lee ES, Cho S, Ku BJ, Rhee MS, Kim BC, et al. Elucidation of Akkermansia muciniphila probiotic traits driven by mucin depletion. Front Microbiol. 2019;10:1137.PubMedPubMedCentralCrossRef
79.
Li F, Wang M, Wang J, Li R, Zhang Y. Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease. Front Cell Infect Microbiol. 2019;9:206.PubMedPubMedCentralCrossRef
80.
Lakshmanan AP, Al Za’abi M, Ali BH, Terranegra A. The influence of the prebiotic gum acacia on the intestinal microbiome composition in rats with experimental chronic kidney disease. Biomed Pharmacother. 2021;133:110992.PubMedCrossRef
81.
Lakshmanan AP, Kohil A, El Assadi F, Al Zaidan S, Al Abduljabbar S, Bangarusamy DK, Al Khalaf F, Petrovski G, Terranegra A. Akkermansia, a possible microbial marker for poor glycemic control in qataris children consuming arabic diet-A pilot study on pediatric T1DM in Qatar. Nutrients. 2021;13:836.PubMedPubMedCentralCrossRef
82.
Ghaffari S, Abbasi A, Somi MH, Moaddab SY, Nikniaz L, Kafil HS, Leylabadlo HE. Akkermansia muciniphila: from its critical role in human health to strategies for promoting its abundance in human gut microbiome. Crit Rev Food Sci Nutr. 2022;1–21.
83.
Ganesh BP, Klopfleisch R, Loh G, Blaut M. Commensal Akkermansia muciniphila exacerbates gut inflammation in salmonella typhimurium-infected gnotobiotic mice. PLoS ONE. 2013;8:e74963.PubMedPubMedCentralCrossRef
84.
Dan X, Mushi Z, Baili W, Han L, Enqi W, Huanhu Z, Shuchun L. Differential analysis of hypertension-associated intestinal microbiota. Int J Med Sci. 2019;16:872–81.PubMedPubMedCentralCrossRef
85.
Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci USA. 2017;114:10713–8.PubMedPubMedCentralCrossRef
86.
Silveira-Nunes G, Durso DF, de Oliveira LRA Jr, Cunha EHM, Maioli TU, Vieira AT, Speziali E, Correa-Oliveira R, Martins-Filho OA, Teixeira-Carvalho A, et al. Hypertension is associated with intestinal microbiota dysbiosis and inflammation in a brazilian population. Front Pharmacol. 2020;11:258.PubMedPubMedCentralCrossRef
87.
Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC, Fortes ZB, Webb RC, Carvalho MH. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci. 2012;122:535–43.CrossRef
88.
Toral M, Gomez-Guzman M, Jimenez R, Romero M, Sanchez M, Utrilla MP, Garrido-Mesa N, Rodriguez-Cabezas ME, Olivares M, Galvez J, Duarte J. The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice. Clin Sci. 2014;127:33–45.CrossRef
89.
Grylls A, Seidler K, Neil J. Link between microbiota and hypertension: focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics. Biomed Pharmacother. 2021;137:111334.PubMedCrossRef
90.
Liu Y, Dai M. Trimethylamine N-oxide generated by the gut microbiota is associated with vascular inflammation: new insights into atherosclerosis. Mediators Inflamm. 2020;2020:4634172.PubMedPubMedCentralCrossRef
91.
92.
Zhang WQ, Wang YJ, Zhang A, Ding YJ, Zhang XN, Jia QJ, Zhu YP, Li YY, Lv SC, Zhang JP. TMA/TMAO in hypertension: novel horizons and potential therapies. J Cardiovasc Transl Res. 2021;14:1117–24.PubMedCrossRef
93.
Roncal C, Martinez-Aguilar E, Orbe J, Ravassa S, Fernandez-Montero A, Saenz-Pipaon G, Ugarte A, de Estella-HermosoMendoza A, Rodriguez JA, Fernandez-Alonso S, et al. Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease. Sci Rep. 2019;9:15580.PubMedPubMedCentralCrossRef
94.
Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, Org E, Wu Y, Li L, Smith JD, et al. gamma-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20:799–812.PubMedPubMedCentralCrossRef
95.
Brunt VE, Gioscia-Ryan RA, Casso AG, VanDongen NS, Ziemba BP, Sapinsley ZJ, Richey JJ, Zigler MC, Neilson AP, Davy KP, Seals DR. Trimethylamine-N-oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and healthy humans. Hypertension. 2020;76:101–12.PubMedCrossRef
96.
Zhou J, Wang D, Li B, Li X, Lai X, Lei S, Li N, Zhang X. Relationship between plasma Trimethylamine N-oxide levels and renal dysfunction in patients with hypertension. Kidney Blood Press Res. 2021;46:421–32.PubMedCrossRef
97.
Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23:107–13.PubMedCrossRef
98.
Luo Y, Zhang Y, Han X, Yuan Y, Zhou Y, Gao Y, Yu H, Zhang J, Shi Y, Duan Y, et al. Akkermansia muciniphila prevents cold-related atrial fibrillation in rats by modulation of TMAO induced cardiac pyroptosis. EBioMedicine. 2022;82:104087.PubMedPubMedCentralCrossRef
99.
Dordevic D, Jancikova S, Vitezova M, Kushkevych I. Hydrogen sulfide toxicity in the gut environment: Meta-analysis of sulfate-reducing and lactic acid bacteria in inflammatory processes. J Adv Res. 2021;27:55–69.PubMedCrossRef
100.
Lv B, Chen S, Tang C, Jin H, Du J, Huang Y. Hydrogen sulfide and vascular regulation—An update. J Adv Res. 2021;27:85–97.PubMedCrossRef
101.
Rosario D, Benfeitas R, Bidkhori G, Zhang C, Uhlen M, Shoaie S, Mardinoglu A. Understanding the representative gut microbiota dysbiosis in metformin-treated type 2 diabetes patients using genome-scale metabolic modeling. Front Physiol. 2018;9:775.PubMedPubMedCentralCrossRef
102.
Sun NL, Xi Y, Yang SN, Ma Z, Tang CS. Plasma hydrogen sulfide and homocysteine levels in hypertensive patients with different blood pressure levels and complications. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:1145–8.PubMed
103.
Shi YX, Chen Y, Zhu YZ, Huang GY, Moore PK, Huang SH, Yao T, Zhu YC. Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2007;293:H2093-2100.PubMedCrossRef
104.
Wang C, Han J, Xiao L, Jin CE, Li DJ, Yang Z. Role of hydrogen sulfide in portal hypertension and esophagogastric junction vascular disease. World J Gastroenterol. 2014;20:1079–87.PubMedPubMedCentralCrossRef
105.
Yan H, Du J, Tang C. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biophys Res Commun. 2004;313:22–7.PubMedCrossRef
106.
Zhao X, Zhang LK, Zhang CY, Zeng XJ, Yan H, Jin HF, Tang CS, Du JB. Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. Hypertens Res. 2008;31:1619–30.PubMedCrossRef
107.
Li L, Bhatia M, Moore PK. Hydrogen sulphide–a novel mediator of inflammation? Curr Opin Pharmacol. 2006;6:125–9.PubMedCrossRef
108.
Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006;20:2118–20.PubMedCrossRef
109.
110.
Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74:120–31.PubMedCrossRef
111.
Lau WL, Kalantar-Zadeh K, Vaziri ND. The gut as a source of inflammation in chronic kidney disease. Nephron. 2015;130:92–8.PubMedCrossRef
112.
113.
Six I, Flissi N, Lenglet G, Louvet L, Kamel S, Gallet M, Massy ZA, Liabeuf S. Uremic toxins and vascular dysfunction. Toxins. 2020;12:404.PubMedCentralCrossRef
114.
Filipska I, Winiarska A, Knysak M, Stompor T. Contribution of gut microbiota-derived uremic toxins to the cardiovascular system mineralization. Toxins. 2021;13:274.PubMedPubMedCentralCrossRef
115.
Ren Z, Fan Y, Li A, Shen Q, Wu J, Ren L, Lu H, Ding S, Ren H, Liu C, et al. Alterations of the human gut microbiome in chronic kidney disease. Adv Sci. 2020;7:2001936.CrossRef
116.
Chen H, Wang MC, Chen YY, Chen L, Wang YN, Vaziri ND, Miao H, Zhao YY. Alisol B 23-acetate attenuates CKD progression by regulating the renin-angiotensin system and gut-kidney axis. Ther Adv Chronic Dis. 2020;11:2040622320920025.PubMedPubMedCentralCrossRef
117.
Rodriguez-Iturbe B, Johnson RJ. The role of renal microvascular disease and interstitial inflammation in salt-sensitive hypertension. Hypertens Res. 2010;33:975–80.PubMedCrossRef
118.
119.
Buford TW, Sun Y, Roberts LM, Banerjee A, Peramsetty S, Knighton A, Verma A, Morgan D, Torres GE, Li Q, Carter CS. Angiotensin (1–7) delivered orally via probiotic, but not subcutaneously, benefits the gut-brain axis in older rats. Geroscience. 2020;42:1307–21.PubMedPubMedCentralCrossRef
120.
Roshanravan N, Mahdavi R, Alizadeh E, Ghavami A, Rahbar Saadat Y, Mesri Alamdari N, Alipour S, Dastouri MR, Ostadrahimi A. The effects of sodium butyrate and inulin supplementation on angiotensin signaling pathway via promotion of Akkermansia muciniphila abundance in type 2 diabetes; a randomized, double-blind, placebo-controlled trial. J Cardiovasc Thorac Res. 2017;9:183–90.PubMedPubMedCentralCrossRef
121.
Duan Y, Prasad R, Feng D, Beli E, Li Calzi S, Longhini ALF, Lamendella R, Floyd JL, Dupont M, Noothi SK, et al. Bone marrow-derived cells restore functional integrity of the gut epithelial and vascular barriers in a model of diabetes and ACE2 deficiency. Circ Res. 2019;125:969–88.PubMedPubMedCentralCrossRef
122.
Suzuki TA, Martins FM, Nachman MW. Altitudinal variation of the gut microbiota in wild house mice. Mol Ecol. 2019;28:2378–90.PubMedCrossRef
123.
Robles-Vera I, Toral M, de la Visitacion N, Sanchez M, Gomez-Guzman M, Munoz R, Algieri F, Vezza T, Jimenez R, Galvez J, et al. Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. Br J Pharmacol. 2020;177:2006–23.PubMedPubMedCentralCrossRef
124.
Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168-175.
125.
Dawes MG, Bartlett G, Coats AJ, Juszczak E. Comparing the effects of white coat hypertension and sustained hypertension on mortality in a UK primary care setting. Ann Fam Med. 2008;6:390–6.PubMedPubMedCentralCrossRef
126.
127.
Konukoglu D, Uzun H. Endothelial dysfunction and hypertension. Adv Exp Med Biol. 2017;956:511–40.PubMedCrossRef
128.
Levine AB, Punihaole D, Levine TB. Characterization of the role of nitric oxide and its clinical applications. Cardiology. 2012;122:55–68.PubMedCrossRef
129.
Rovella V, Rodia G, Di Daniele F, Cardillo C, Campia U, Noce A, Candi E, Della-Morte D, Tesauro M. Association of gut hormones and microbiota with vascular dysfunction in obesity. Nutrients. 2021;13:613.PubMedPubMedCentralCrossRef
130.
Wang Z, Wu F, Zhou Q, Qiu Y, Zhang J, Tu Q, Zhou Z, Shao Y, Xu S, Wang Y, Tao J. Berberine improves vascular dysfunction by inhibiting Trimethylamine-N-oxide via regulating the gut microbiota in angiotensin II-induced hypertensive mice. Front Microbiol. 2022;13:814855.PubMedPubMedCentralCrossRef
131.
Catry E, Bindels LB, Tailleux A, Lestavel S, Neyrinck AM, Goossens JF, Lobysheva I, Plovier H, Essaghir A, Demoulin JB, et al. Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut. 2018;67:271–83.PubMedCrossRef
132.
Lee DM, Battson ML, Jarrell DK, Hou S, Ecton KE, Weir TL, Gentile CL. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol. 2018;17:62.PubMedPubMedCentralCrossRef
133.
Haywood NJ, Luk C, Bridge KI, Drozd M, Makava N, Skromna A, Maccannell A, Ozber CH, Warmke N, Wilkinson CG, et al. Endothelial IGF-1 receptor mediates crosstalk with the gut wall to regulate microbiota in obesity. EMBO Rep. 2021;22:e50767.PubMedPubMedCentralCrossRef
134.
Neyrinck AM, Catry E, Taminiau B, Cani PD, Bindels LB, Daube G, Dessy C, Delzenne NM. Chitin-glucan and pomegranate polyphenols improve endothelial dysfunction. Sci Rep. 2019;9:14150.PubMedPubMedCentralCrossRef
135.
D’Addario C, Maccarrone M. Alcohol and epigentic modulations. Cambridge: Academic Press; 2016;261–273.
136.
137.
Richard MA, Huan T, Ligthart S, Gondalia R, Jhun MA, Brody JA, Irvin MR, Marioni R, Shen J, Tsai PC, et al. DNA Methylation analysis identifies loci for blood pressure regulation. Am J Hum Genet. 2017;101:888–902.PubMedPubMedCentralCrossRef
138.
Nanduri J, Peng YJ, Wang N, Khan SA, Semenza GL, Kumar GK, Prabhakar NR. Epigenetic regulation of redox state mediates persistent cardiorespiratory abnormalities after long-term intermittent hypoxia. J Physiol. 2017;595:63–77.PubMedCrossRef
139.
Pushpakumar S, Kundu S, Narayanan N, Sen U. DNA hypermethylation in hyperhomocysteinemia contributes to abnormal extracellular matrix metabolism in the kidney. FASEB J. 2015;29:4713–25.PubMedPubMedCentralCrossRef
140.
Cardinale JP, Sriramula S, Pariaut R, Guggilam A, Mariappan N, Elks CM, Francis J. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension. 2010;56:437–44.PubMedCrossRef
141.
Won KJ, Jung SH, Jung SH, Lee KP, Lee HM, Lee DY, Park ES, Kim J, Kim B. DJ-1/park7 modulates vasorelaxation and blood pressure via epigenetic modification of endothelial nitric oxide synthase. Cardiovasc Res. 2014;101:473–81.PubMedCrossRef
142.
Jabs S, Biton A, Becavin C, Nahori MA, Ghozlane A, Pagliuso A, Spano G, Guerineau V, Touboul D, Giai Gianetto Q, et al. Impact of the gut microbiota on the m(6)A epitranscriptome of mouse cecum and liver. Nat Commun. 2020;11:1344.PubMedPubMedCentralCrossRef
143.
144.
Mentella MC, Scaldaferri F, Pizzoferrato M, Gasbarrini A, Miggiano GAD. Nutrition, IBD and gut microbiota: a review. Nutrients. 2020;12:944.PubMedCentralCrossRef
145.
Leeming ER, Johnson AJ, Spector TD, Le Roy CI. Effect of diet on the gut microbiota: rethinking intervention duration. Nutrients. 2019;11:2862.PubMedCentralCrossRef
146.
Filippou CD, Tsioufis CP, Thomopoulos CG, Mihas CC, Dimitriadis KS, Sotiropoulou LI, Chrysochoou CA, Nihoyannopoulos PI, Tousoulis DM. Dietary approaches to stop hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr. 2020;11:1150–60.PubMedPubMedCentralCrossRef
147.
Ozemek C, Laddu DR, Arena R, Lavie CJ. The role of diet for prevention and management of hypertension. Curr Opin Cardiol. 2018;33:388–93.PubMedCrossRef
148.
Maifeld A, Bartolomaeus H, Lober U, Avery EG, Steckhan N, Marko L, Wilck N, Hamad I, Susnjar U, Mahler A, et al. Fasting alters the gut microbiome reducing blood pressure and body weight in metabolic syndrome patients. Nat Commun. 1970;2021:12.
149.
Velikonja A, Lipoglavsek L, Zorec M, Orel R, Avgustin G. Alterations in gut microbiota composition and metabolic parameters after dietary intervention with barley beta glucans in patients with high risk for metabolic syndrome development. Anaerobe. 2019;55:67–77.PubMedCrossRef
150.
Guevara-Cruz M, Flores-Lopez AG, Aguilar-Lopez M, Sanchez-Tapia M, Medina-Vera I, Diaz D, Tovar AR, Torres N. Improvement of lipoprotein profile and metabolic endotoxemia by a lifestyle intervention that modifies the gut microbiota in subjects with metabolic syndrome. J Am Heart Assoc. 2019;8:e012401.PubMedPubMedCentralCrossRef
151.
Psaltopoulou T, Naska A, Orfanos P, Trichopoulos D, Mountokalakis T, Trichopoulou A. Olive oil, the Mediterranean diet, and arterial blood pressure: the Greek European Prospective Investigation into Cancer and Nutrition (EPIC) study. Am J Clin Nutr. 2004;80:1012–8.PubMedCrossRef
152.
Nunez-Cordoba JM, Valencia-Serrano F, Toledo E, Alonso A, Martinez-Gonzalez MA. The Mediterranean diet and incidence of hypertension: the Seguimiento Universidad de Navarra (SUN) study. Am J Epidemiol. 2009;169:339–46.PubMedCrossRef
153.
Tzima N, Pitsavos C, Panagiotakos DB, Skoumas J, Zampelas A, Chrysohoou C, Stefanadis C. Mediterranean diet and insulin sensitivity, lipid profile and blood pressure levels, in overweight and obese people; the Attica study. Lipids Health Dis. 2007;6:22.PubMedPubMedCentralCrossRef
154.
155.
Tagliamonte S, Laiola M, Ferracane R, Vitale M, Gallo MA, Meslier V, Pons N, Ercolini D, Vitaglione P. Mediterranean diet consumption affects the endocannabinoid system in overweight and obese subjects: possible links with gut microbiome, insulin resistance and inflammation. Eur J Nutr. 2021;60:3703–16.PubMedPubMedCentralCrossRef
156.
Obach RS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacol Rev. 2013;65:578–640.PubMedCrossRef
157.
158.
Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69:1510–9.PubMedCrossRef
159.
Li Y, Zhao D, Qian M, Liu J, Pan C, Zhang X, Duan X, Zhang Y, Jia W, Wang L. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. Br J Pharmacol. 2022;179:2054–77.PubMedCrossRef
160.
Neto DPA, Bosque BP, de Godoy JVP, Rodrigues PV, Meneses DD, Tostes K, Costa Tonoli CC, de Carvalho HF, Gonzalez-Billault C, de Castro FM. Akkermansia muciniphila induces mitochondrial calcium overload and alpha-synuclein aggregation in an enteroendocrine cell line. iScience. 2022;25:103908.PubMedPubMedCentralCrossRef
161.
Chen HQ, Gong JY, Xing K, Liu MZ, Ren H, Luo JQ. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in antihypertensive treatment. Front Med. 2021;8:742394.CrossRef
162.
Khan TJ, Ahmed YM, Zamzami MA, Siddiqui AM, Khan I, Baothman OAS, Mehanna MG, Kuerban A, Kaleemuddin M, Yasir M. Atorvastatin treatment modulates the gut microbiota of the hypercholesterolemic patients. OMICS. 2018;22:154–63.PubMedCrossRef
163.
Anani H, Zgheib R, Hasni I, Raoult D, Fournier PE. Interest of bacterial pangenome analyses in clinical microbiology. Microb Pathog. 2020;149:104275.PubMedCrossRef
164.
Bukhari SAR, Irfan M, Ahmad I, Chen L. Comparative genomics and pan-genome driven prediction of a reduced genome of Akkermansia muciniphila. Microorganisms. 2022;10:1350.PubMedPubMedCentralCrossRef
165.
Guo X, Li S, Zhang J, Wu F, Li X, Wu D, Zhang M, Ou Z, Jie Z, Yan Q, et al. Genome sequencing of 39 Akkermansia muciniphila isolates reveals its population structure, genomic and functional diverisity, and global distribution in mammalian gut microbiotas. BMC Genomics. 2017;18:800.PubMedPubMedCentralCrossRef
166.
Becken B, Davey L, Middleton DR, Mueller KD, Sharma A, Holmes ZC, Dallow E, Remick B, Barton GM, David LA, et al. Genotypic and phenotypic diversity among human isolates of Akkermansia muciniphila. mBio. 2021;12:e00478–21.PubMedPubMedCentralCrossRef
167.
Carmody RN, Turnbaugh PJ. Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest. 2014;124:4173–81.PubMedPubMedCentralCrossRef
168.
Liu S, Rezende RM, Moreira TG, Tankou SK, Cox LM, Wu M, Song A, Dhang FH, Wei Z, Costamagna G, Weiner HL. Oral administration of miR-30d from feces of MS patients suppresses MS-like symptoms in mice by expanding Akkermansia muciniphila. Cell Host Microbe. 2019;26(779–794):e778.
169.
Sharma A, Buschmann MM, Gilbert JA. Pharmacomicrobiomics: the holy grail to variability in drug response? Clin Pharmacol Ther. 2019;106:317–28.PubMedCrossRef
170.
Ding R, Xiao Z, Jiang Y, Yang Y, Ji Y, Bao X, Xing K, Zhou X, Zhu S. Calcitriol ameliorates damage in high-salt diet-induced hypertension: Evidence of communication with the gut-kidney axis. Exp Biol Med (Maywood) 2022, 247:624-40CrossRef
171.
Leng Y, Yi M, Fan J, Bai Y, Ge Q, Yao G. Effects of acute intra-abdominal hypertension on multiple intestinal barrier functions in rats. Sci Rep 2016, 6:22814. PubMedPubMedCentralCrossRef
172.
173.
Abboud FM, Cicha MZ, Ericsson A, Chapleau MW, Singh MV. Altering Early Life Gut Microbiota Has Long-Term Effect on Immune System and Hypertension in Spontaneously Hypertensive Rats. Front Physiol 2021, 12:752924. PubMedPubMedCentralCrossRef
174.
Singh A, Zapata RC, Pezeshki A, Workentine ML, Chelikani PK. Host genetics and diet composition interact to modulate gut microbiota and predisposition to metabolic syndrome in spontaneously hypertensive stroke-prone rats. FASEB J 2019, 33:6748-66. PubMedCrossRef
175.
Li P, Cai X, Xiao N, Ma X, Zeng L, Zhang LH, Xie L, Du B. Sacha inchi (Plukenetia volubilis L.) shell extract alleviates hypertension in association with the regulation of gut microbiota. Food Funct 2020, 11:8051-67. CrossRef
176.
Wu D, Ding L, Tang X, Wang W, Chen Y, Zhang T. Baicalin Protects Against Hypertension-Associated Intestinal Barrier Impairment in Part Through Enhanced Microbial Production of Short-Chain Fatty Acids. Front Pharmacol 2019, 10:1271. PubMedPubMedCentralCrossRef
177.
Thomaz FS, Altemani F, Panchal SK, Worrall S, Dekker Nitert M. The influence of wasabi on the gut microbiota of high-carbohydrate, high-fat diet-induced hypertensive Wistar rats. J Hum Hypertens 2021, 35:170-80. PubMedCrossRef
178.
de Araujo Henriques Ferreira G, Magnani M, Cabral L, Brandao LR, Noronha MF, de Campos Cruz J, de Souza EL, de Brito Alves JL. Potentially Probiotic Limosilactobacillus fermentum Fruit-Derived Strains Alleviate Cardiometabolic Disorders and Gut Microbiota Impairment in Male Rats Fed a High-Fat Diet. Probiotics Antimicrob Proteins 2022, 14:349-59. PubMedCrossRef
179.
McGavigan AK, Henseler ZM, Garibay D, Butler SD, Jayasinghe S, Ley RE, Davisson RL, Cummings BP. Vertical sleeve gastrectomy reduces blood pressure and hypothalamic endoplasmic reticulum stress in mice. Dis Model Mech 2017, 10:235-43. PubMedPubMedCentral
180.
Nakai M, Ribeiro RV, Stevens BR, Gill P, Muralitharan RR, Yiallourou S, Muir J, Carrington M, Head GA, Kaye DM, Marques FZ. Essential Hypertension Is Associated With Changes in Gut Microbial Metabolic Pathways: A Multisite Analysis of Ambulatory Blood Pressure. HTN 2021, 78:804-15.
181.
Calderon-Perez L, Gosalbes MJ, Yuste S, Valls RM, Pedret A, Llaurado E, Jimenez-Hernandez N, Artacho A, Pla-Paga L, Companys J, et al. Gut metagenomic and short chain fatty acids signature in hypertension: a cross-sectional study. Sci Rep 2020, 10:6436. PubMedPubMedCentralCrossRef
182.
Fei N, Bernabe BP, Lie L, Baghdan D, Bedu-Addo K, Plange-Rhule J, Forrester TE, Lambert EV, Bovet P, Gottel N, et al. The human microbiota is associated with cardiometabolic risk across the epidemiologic transition. PLoS One 2019, 14:e0215262.PubMedPubMedCentralCrossRef
183.
184.
Zhong HJ, Zeng HL, Cai YL, Zhuang YP, Liou YL, Wu Q, He XX. Washed Microbiota transplantation Lowers Blood Pressure in Patients With Hypertension. Front Cell Infect Microbiol 2021, 11:679624. PubMedPubMedCentralCrossRef
Metadata
Title
The potential impact of a probiotic: Akkermansia muciniphila in the regulation of blood pressure—the current facts and evidence
Authors
Arun Prasath Lakshmanan
Selvasankar Murugesan
Souhaila Al Khodor
Annalisa Terranegra
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03631-0

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management

Research

Single-cell N6-methyladenosine regulator patterns guide intercellular communication of tumor microenvironment that contribute to colorectal cancer progression and immunotherapy

Research

High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?

Methodology

Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product

Research

Integrated weighted gene coexpression network analysis identifies Frizzled 2 (FZD2) as a key gene in invasive malignant pleomorphic adenoma

Research

Characteristics of the sputum microbiome in COPD exacerbations and correlations between clinical indices
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits